Showing results (101-110 of 156) with videos related to

Sort By:
Pageof 16
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 22, 2013
Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivoArnaud Zaldumbide, Gonnie Alkemade, Françoise Carlotti, et al.
Diabetes|January 24, 2022
Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 DiabetesYuk-Fun Liu, Jake Powrie, Sefina Arif, et al.
European Journal of Immunology|January 13, 2022
Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetesJennie H M Yang, Kirsten A Ward-Hartstonge, Daniel J Perry, et al.
Immunotherapy Advances|January 24, 2022
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetesAshish K Marwaha, Samuel Chow, Anne M Pesenacker, et al.
Frontiers in Immunology|July 17, 2018
Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-CellsGarry Dolton, Efthalia Zervoudi, Cristina Rius, et al.
The Journal of Experimental Medicine|May 2, 2012
Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammationChung-Ching Chu, Niwa Ali, Panagiotis Karagiannis, et al.
Diabetologia|August 4, 2017
Understanding and preventing type 1 diabetes through the unique working model of TrialNetManuela Battaglia, Mark S Anderson, Jane H Buckner, et al.
The Journal of Biological Chemistry|November 22, 2011
A single autoimmune T cell receptor recognizes more than a million different peptidesLinda Wooldridge, Julia Ekeruche-Makinde, Hugo A van den Berg, et al.
BMJ Open|April 7, 2018
Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohortVassiliki Bravis, Akaal Kaur, Helen C Walkey, et al.
Science Translational Medicine|October 13, 2017
An analysis of IL-36 signature genes and individuals with <i>IL1RL2</i> knockout mutations validates IL-36 as a psoriasis therapeutic targetSatveer K Mahil, Marika Catapano, Paola Di Meglio, et al.
Pageof 16